Sichenzia Ross Friedman Ference LLP Advises Sorrento Therapeutics, Inc. on $25.0 million Public Offering of Common Stock

NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.

Media Contact
pr@srf.law
212-930-9700

[starbox id=1]